In a pivotal move, Pfizer has agreed to price newly launched drugs at parity with prices in comparable developed nations under a most-favored nation pricing agreement negotiated with the Trump administration. This deal aims to lower costs for Medicaid programs and signals a shift in drug pricing strategies. While Pfizer leads this initiative, other major pharmaceutical companies are anticipated to follow suit. Industry observers also note strategic pricing adjustments overseas to protect U.S. market revenues, highlighting the complex interplay between global drug pricing policies and market dynamics.